“It’s Over, Novo!” Eli Lilly’s Lightsaber Cuts Novo Nordisk Down to Size (After Horrible Blunder)

“It’s over, Anakin Novo! I have the high ground!” That’s probably what Eli Lilly’s execs were thinking as they watched Novo Nordisk’s stock plummet over 24% this morning… a historic nosedive for the Danish pharmaceutical powerhouse. So what was the culprit this time? None other than disappointing trial results for their experimental weight-loss drug, CagriSema. If this were Star Wars, Eli Lilly would be Obi-Wan, lightsaber in hand, watching Novo’s Anakin flail helplessly in a sea of unmet expectations.

Here’s the backstory: Novo Nordisk had big hopes for CagriSema, a combination of semaglutide (the magic ingredient in their hit drugs Wegovy and Ozempic) and cagrilintide, a hormone designed to keep you feeling fuller longer. Early hype had Novo forecasting a 25% weight loss in trial patients… enough to make even Ozempic look obsolete (so yeah a lot of money on the line). Instead, the drug delivered a respectable, but not earth-shattering, 22.7% weight reduction (and you know what happens when you overpromise and underdeliver).

Novo’s stock hit the mat hard, dropping 27% at one point this morning. To put that in perspective, the company lost over a quarter of its value in a single session. That’s like losing your fantasy football league because your star quarterback tore an ACL… only in Novo’s case, it’s a multibillion-dollar drug trial falling short. Novo’s CEO, Lars Fruergaard Jørgensen (Dutch much?), tried to put a positive spin on it, noting that 40% of patients achieved 25% weight loss. But when you’ve hyped the drug as “best in class,” falling short of the crown feels like an uppercut from your rival.

On the other hand, Eli Lilly’s Mounjaro (tirzepatide) sits comfortably atop the weight-loss leaderboard. Mounjaro’s phase 3 trials showed a 22.5% average weight loss… essentially on par with CagriSema, but without the same hype-driven letdown. And let’s not forget Zepbound, Lilly’s other contender, which delivered a golf clap worthy 20.2% weight loss compared to Wegovy’s 13.7% in direct trials. That’s a 47% difference for those keeping score at home.

It gets better (for Lilly, at least). The GLP-1 weight-loss market ballooned to $24 billion in 2023, and Lilly’s diversified lineup and robust pipeline (including experimental drugs like orforglipron and retatrutide) position it as the clear Jedi master in this duel. Novo’s relying heavily on CagriSema to claw back market share, but as Friday’s results show, hope is a fragile strategy. Novo Nordisk isn’t out of the fight yet, but it’s definitely nursing a few burns. The company’s flagship Wegovy still leads the market with $5.4 billion in revenue for the first nine months of 2024, but Lilly’s Zepbound is closing the gap fast, bringing in $3 billion since its approval just last November.

For investors, this clash of pharma titans is far from over. But as of now, Eli Lilly has the high ground… and unless Novo can engineer a major comeback, it might just stay that way. Just don’t try to jump over Obi-Wan (we all know how that ends).

PS: Yesterday, our Stocks.News Premium members hit the jackpot with a Toronto biotech stock nobody cared about Wednesday. Our system flagged it for absurdly high short interest—basically, Wall Street’s equivalent of leaving the back door wide open—and then, boom, they casually announced a licensing deal with a major pharma company. By lunchtime, the stock shot from $2 to $6.80, handing out 240% gains (not bad right?).

If you’re tired of missing out on plays like this, maybe it’s time to join Stocks.News Premium. You’ll get trade alerts like this twice a week, plus our Insider Trading Tool that tracks everyone from overpaid CEOs to your favorite Congress members cashing in on their "foresight." Oh, and unlike Bloomberg, we don’t charge a small fortune for the privilege. They might have fancy terminals, but do they deliver breaking trade alerts and tools that actually move the needle? Didn’t think so. Go here to become a Stocks.News premium member now.

Stock.News does not have positions in companies mentioned.